To present a practical, easy-to-implement clinical framework designed to support evidence-based quality prescribing for people with early psychosis.
Method:
Identification and explanation of key principles relating to evidence-based pharmacotherapy for people with early psychosis. These were derived from the literature, practice guidelines and clinical experience.
Results:
Key principles include (1) medication choice informed by adverse effects; (2) metabolic monitoring at baseline and at regular intervals; (3) comprehensive and regular medication risk–benefit assessment and psychoeducation; (4) early consideration of long-acting injectable formulations (preferably driven by informed patient choice); (5) identification and treatment of comorbid mood disorders and (6) early consideration of clozapine when treatment refractory criteria are met.
Conclusions:
Current prescribing practices do not align with the well-established evidence for quality pharmacotherapy in early psychosis. Adopting evidence-based prescribing practices for people with early psychosis will improve outcomes.
ZhuYKrauseMHuhnM, et al. Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. Lancet Psychiatry2017; 4: 694–705.
2.
Abdel-BakiAOuellet-PlamondonCMallaA. Pharmacotherapy challenges in patients with first-episode psychosis. J Affect Disord2012; 138: S3–S14.
3.
SommerIOomenPHasanA. Maintenance treatment for patients with a first psychotic episode. Curr Opin Psychiatry2019; 32: 147–156.
4.
WhaleRHarrisMKavanaghG, et al. Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study. BJPsych Open2016; 2: 323–329.
5.
Early Psychosis Guidelines Writing Group and EPPIC National Support Program. Australian Clinical Guidelines for Early Psychosis, 2nd Edition Update. Melbourne: Orygen, The National Centre of Excellence in Youth Mental Health, 2016.
6.
ScottJBakerALimC, et al. Effect of sodium benzoate vs placebo among individuals with early psychosis: a randomized clinical trial. JAMA Netw. Open2020; 3: e2024335.
7.
CurtisJNewallHDSamarasK. The heart of the matter: cardiometabolic care in youth with psychosis. Early Interv Psychiatry2012; 6: 347–353.
8.
TiihonenJMittendorfer-RutzEMajakM, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29823 patients with schizophrenia. JAMA Psychiatry2017; 74: 686–693.
9.
JauharSYoungA. Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy. Int J Bipolar Disord2019; 7: 10.
10.
AltamuraABuoliMCaldiroliA, et al. Misdiagnosis, duration of untreated illness (DUI) and outcome in bipolar patients with psychotic symptoms: a naturalistic study. J Affect Disord2015; 182.
11.
CottonSLambertMSchimmelmannB, et al. Depressive symptoms in first episode schizophrenia spectrum disorder. Schizophr Res2012; 134: 20–26.
12.
KanaharaNYamanakaHSuzukiT, et al. First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort. BMC Psychiatry2018; 18: 274–274.
13.
GalletlyCCastleDDarkF, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust NZJ Psychiatry2016; 50: 410–472.
14.
KishiTIkutaTMatsuiY, et al. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis. Psychol Med2019; 49: 772–779.
15.
TakeuchiHSiuCRemingtonG, et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology2019; 44: 1036–1042.
16.
PillingerTMcCutcheonRVanoL, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry2020; 7: 64–77.
17.
HjorthøjCStürupAMcGrathJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry2017; 4: 295–301.
18.
ThompsonAHetrickSAlvarez-JimenezM, et al. Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis. Aust NZJ Psychiatry2011; 45: 740–748.
19.
SubotnikKCasausLVenturaJ, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry2015; 72: 822–829.
20.
KishimotoTRobenzadehALeuchtC, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophrenia Bulletin2014; 40.
21.
Abdel-BakiAMedranoSMarandaC, et al. Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. Int Clin Psychopharmacol2020; 35: 221–228.
22.
BlackwoodCSangaPNuamahI, et al. Patients’ preferences for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire. Patient Prefer Adherence2020; 14: 1093–1102.
23.
MacmillanIHowellsLKaleK, et al. Social and symptomatic outcomes of first-episode bipolar psychoses in an early intervention service. Early Interv Psychiatry2007; 1: 79–87.
24.
PostRYathamLVietaE, et al. Beyond evidence-based treatment of bipolar disorder: rational pragmatic approaches to management. Bipolar Disorders2019; 21: 650–659.
25.
LahteenvuoMTanskanenATaipaleH, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry2018; 75: 347–355.
26.
BerkMDaglasRDandashO, et al. Quetiapine v. Lithium in the maintenance phase following a first episode of mania: randomised controlled trial. Br J Psychiatry2017; 210: 413–421.
27.
XiaJMerinderLBelgamwarM. Psychoeducation for schizophrenia. Cochrane Database Syst Rev2011; 6.
28.
Yesufu-UdechukuAHarrisonBMayo-WilsonE, et al. Interventions to improve the experience of caring for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry2015; 206: 268–274.
29.
TessierABoyerLHuskyM, et al. Medication adherence in schizophrenia: the role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. Psychiatry Res2017; 257: 315–321.
30.
KeatingDMcWilliamsSSchneiderI, et al. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open2017; 7: e013881.
31.
ThienKO’DonoghueB. Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: a literature review. Early Interv Psychiatry2019; 13: 18–23.
32.
StokesIGriffithsSJonesR, et al. Prevalence of treatment resistance and clozapine use in early intervention services. BJPsych Open2020; 6: e107.
33.
YoshimuraBYadaYSoR, et al. The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. Psychiatry Res2017; 250: 65–70.
34.
AgidOSchulzeLArenovichT, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. European Neuropsychopharmacology2013; 23: 1017–1022.
